Stock Traders Purchase High Volume of Call Options on Xeris Biopharma (NASDAQ:XERS)

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) saw unusually large options trading on Tuesday. Stock investors purchased 9,035 call options on the stock. This is an increase of approximately 1,543% compared to the typical daily volume of 550 call options.

Insider Activity at Xeris Biopharma

In related news, insider Kevin Mcculloch sold 90,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $8.03, for a total value of $722,700.00. Following the completion of the sale, the insider directly owned 1,691,126 shares of the company’s stock, valued at $13,579,741.78. This represents a 5.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $6.06, for a total value of $101,002.02. Following the completion of the sale, the insider directly owned 1,176,506 shares of the company’s stock, valued at approximately $7,129,626.36. This trade represents a 1.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 206,500 shares of company stock valued at $1,463,405. Corporate insiders own 4.35% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of XERS. Divisadero Street Capital Management LP acquired a new stake in shares of Xeris Biopharma during the third quarter worth $3,308,000. Apella Capital LLC increased its stake in Xeris Biopharma by 2,359.0% in the 4th quarter. Apella Capital LLC now owns 245,897 shares of the company’s stock valued at $1,930,000 after buying an additional 235,897 shares during the period. Granahan Investment Management LLC purchased a new position in Xeris Biopharma during the 3rd quarter worth $2,850,000. Vanguard Group Inc. raised its position in Xeris Biopharma by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after buying an additional 1,358,760 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in shares of Xeris Biopharma in the 3rd quarter worth $739,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Stock Performance

NASDAQ XERS traded up $0.51 during trading on Tuesday, reaching $8.88. The company’s stock had a trading volume of 1,668,490 shares, compared to its average volume of 1,899,138. The business’s fifty day moving average price is $6.65 and its 200-day moving average price is $6.64. Xeris Biopharma has a twelve month low of $4.66 and a twelve month high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of 147.92 and a beta of 0.62.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The business had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. As a group, analysts anticipate that Xeris Biopharma will post 0.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.